CAJ | 학술논문

目的：检测肺癌患者血清淋巴管内皮透明质酸受体1( LYVE-1)水平,并探讨血清LYVE-1用于判断肺癌患者是否发生淋巴结转移及预测患者预后的临床意义。方法采用酶联免疫法( ELISA)检测57例肺癌患者血清中LYVE-1的水平,同时分析血清LYVE-1水平与患者临床病理特征的关系,通过受试者工作曲线( ROC)分析血清LYVE-1用于判断肺癌患者是否发生淋巴结转移的可行性,Kaplan-Meier法进行生存分析,评价LYVE-1用于预测病人预后的临床意义。结果肺癌患者血清LYVE-1为1625．0±343．0 pg/mL；血清LYVE-1与肺癌患者性别、肿瘤组织学分型、血清CEA和CA125无统计学差异(P>0．05),而与TNM分期、淋巴结转移和远处转移情况有关( P<0．05)；血清LYVE-1用于诊断肺癌患者发生淋巴结转移的曲线下面积为0．728(95% CI：0．685-0．747,P<0．05)；LYVE-1的为1821 pg/mL时,其诊断的敏感性为79%,特异性为68%；血清LYVE-1大于1821pg/mL的肺癌患者预后要比血清LYVE-1小于1821 pg/mL的肺癌患者预后差,两组总生存时间有统计学差异(P=0．035)。结论血清LYVE-1可用于确定肺癌患者是否发生淋巴结转移,并可用于评估病人预后。
목적：검측폐암환자혈청림파관내피투명질산수체1( LYVE-1)수평,병탐토혈청LYVE-1용우판단폐암환자시부발생림파결전이급예측환자예후적림상의의。방법채용매련면역법( ELISA)검측57례폐암환자혈청중LYVE-1적수평,동시분석혈청LYVE-1수평여환자림상병리특정적관계,통과수시자공작곡선( ROC)분석혈청LYVE-1용우판단폐암환자시부발생림파결전이적가행성,Kaplan-Meier법진행생존분석,평개LYVE-1용우예측병인예후적림상의의。결과폐암환자혈청LYVE-1위1625．0±343．0 pg/mL；혈청LYVE-1여폐암환자성별、종류조직학분형、혈청CEA화CA125무통계학차이(P>0．05),이여TNM분기、림파결전이화원처전이정황유관( P<0．05)；혈청LYVE-1용우진단폐암환자발생림파결전이적곡선하면적위0．728(95% CI：0．685-0．747,P<0．05)；LYVE-1적위1821 pg/mL시,기진단적민감성위79%,특이성위68%；혈청LYVE-1대우1821pg/mL적폐암환자예후요비혈청LYVE-1소우1821 pg/mL적폐암환자예후차,량조총생존시간유통계학차이(P=0．035)。결론혈청LYVE-1가용우학정폐암환자시부발생림파결전이,병가용우평고병인예후。
Objective To detect the level of serum lymphatic vessel endothelial hyaluronan receptor-1 ( LY-VE-1) in patients with lung cancer, and to investigate the significance of serum LYVE-1 on the metastasis and prog-nosis of lung cancer. Methods The level of serum LYVE-1 in 57 lung cancer patients were detected by Enzyme-linked immunosorbent assay ( ELISA) . The clinical and pathologic features with the level of LYVE-1 were analyzed. The specificity and sensitivity of serum LYVE-1 to determine whether lymph node metastasis or not were analyzed by receiver operating characteristic ( ROC) curve. Kaplan-Meier method was used to evaluate overall survival according to cut-off serum LYVE-1. Results The level of serum LYVE-1 was 1625. 0 ± 343. 0 pg/mL, which showed no sig-nificant correlation with sexuality, tumor histological type, serum CEA and CA125 (P>0. 05), but correlated with high cancer staging, occurrence of lymph-node metastases, and occurrence of distant metastases (P<0. 05). Taking 3542 pg/ml of LYVE1 as the cut-off point, the sensitivity was 68% and 79% of specificity, with an area under the curve (AUC) of 0. 728 (P<0. 05). Conclusion The serum level of LYVE-1 can be a helpful biomarker to identify lymph node metastases and evaluate the prognosis of patients with lung cancer.